Redeye leaves a short comment on WntResearch’s extraordinary general meeting.
Redeye comments on WntResearch’s Q4 2024 report. The report was undramatic, which was expected in our view as the focus is on the reverse ac...
Redeye comments on WntResearch’s conditional reverse acquisition of OPSY AB.
Redeye provides a note following WntResearch’s Q3 2024 report.
Redeye provides a comment on WntResearch’s update regarding the work in progress.
Redeye provides a longer note following WntResearch’s failed phase 2 study and CEO interview.
Redeye provides a brief comment on WntResearch’s initial phase 2 data.
Redeye provides an update following WntResearch’s Q2 report.
Redeye initiates coverage of WntResearch, a Swedish biotechnology company specialised in oncology.
WntResearch, som genomför en fas 2-studie med läkemedelskandidaten Foxy-5 för patienter som drabbats av cancer i tjocktarmen, har efter nya ...
